← Back to Search

Alkylating agents

Pembrolizumab for Non-Small Cell Lung Cancer

Phase 1

Waitlist Available

Research Sponsored by Nathan Pennell, MD, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the safety of giving chemoradiotherapy followed by consolidation pembrolizumab after surgery in people with NSCLC.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients with grade 3 pulmonary toxicity or grade 4 other non hematologic toxicity

Secondary outcome measures

Complete Pathologic Response Rate

Nodal Downstaging at Surgery

Objective Response Rate

+2 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183

21%

Fatigue

13%

Nausea

11%

Back pain

Shortness of Breath

Anemia

Abdominal pain

Diarrhea

Pneumonia

Kidney Injury and/or Infection

Dyspnea

Weight Loss

Malnutrition, Hypercalcemia and Weakness

Pneumothorax

Intractable pain, back pain, hip pain

Activated partial thromboplastin time prolonged

Pleural effusion

Atrial fibrillation with rapid ventricular response

Thrombocytopenia

Respiratory failure

Skin rash

colitis

100%

80%

60%

40%

20%

Study treatment Arm

Single Arm

Trial Design

1Treatment groups

Experimental Treatment

Group I: Resectable PatientsExperimental Treatment4 Interventions

Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Etoposide

FDA approved

Pembrolizumab

FDA approved

Radiation

2003

Completed Phase 3

~1020

Cisplatin

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Nathan Pennell, MD, PhDLead Sponsor

2 Previous Clinical Trials

45 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this study actively seeking participants?

"This study is currently not open for recruitment. It was initially published on May 19th 2017 and last modified August 19th, 2022. If you are searching for alternative trials, there are 1909 lung cancer studies and 1764 Pembrolizumab clinical trials actively recruiting participants."

Answered by AI

What maladies does Pembrolizumab typically address?

"Pembrolizumab is commonly employed to treat malignant melanoma of the skin, but also proves effective in treating merkel cell cancer, recurrent cervical neoplasms and refractory/relapsed mediastinal large B-cell lymphoma."

Answered by AI

What is the total enrolment for this research initiative?

"Presently, this medical trial is not taking any more patients. Initially posted on May 19th 2017 and updated lastly on August 19th 2022, it no longer seeks to enrol participants. However those looking for other studies may find 1909 studies recruiting lung cancer sufferers and 1764 seeking Pembrolizumab users respectively."

Answered by AI

Is there any risk associated with administering Pembrolizumab to patients?

"The safety of Pembrolizumab has been determined to be a 1 on the scale from 1-3, as this trial is in its initial phase with limited evidence for both efficacy and security."

Answered by AI

What have prior investigations elucidated about Pembrolizumab?

"Presently, 405 Phase 3 clinical trials for Pembrolizumab are underway with the majority situated in Shanghai. Simultaneously, there are 1764 active studies of this drug being conducted across 77,414 locations around the world."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC

Nathan Pennell, MD, PhD 2017. "Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02987998.